Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | CCKBR | P32239 | 2/20 | 0.49 |
| ▸ | NPY1R | P25929 | 3/20 | 0.49 |
| ▸ | NPY2R | P49146 | 3/20 | 0.49 |
| ▸ | NPY4R | P50391 | 3/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31484223 | 0.97 | ERAP2 (0.51) | ERAP2MMP1MMP2MMP8CCKBR | |
| SCHEMBL31074790 | 0.97 | MMP1 (0.51) | ERAP2MMP1MMP2MMP8NPY1R | |
| SCHEMBL29577026 | 0.96 | ACE (0.52) | ERAP2NPY1RNPY2RNPY4RACE | |
| SCHEMBL30200105 | 0.96 | ACE (0.52) | ERAP2NPY1RNPY2RNPY4RACE | |
| SCHEMBL30085020 | 0.96 | ACE (0.52) | ERAP2NPY1RNPY2RNPY4RACE | |
| SCHEMBL31607064 | 0.95 | ERAP2 (0.52) | ERAP2MMP1MMP2MMP8CCKBR | |
| SCHEMBL30688662 | 0.95 | MMP1 (0.51) | ERAP2MMP1MMP2MMP8ACE | |
| SCHEMBL30053160 | 0.95 | KISS1R (0.50) | ERAP2MMP1MMP2MMP8CCKBR | |
| SCHEMBL30389170 | 0.95 | NPY1R (0.53) | ERAP2NPY1RNPY2RNPY4RACE | |
| SCHEMBL29799876 | 0.95 | NPY1R (0.53) | ERAP2NPY1RNPY2RNPY4RACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | MC3R, MC4R, MC1R | ERAP2 1323/4885MMP1 4289/4885MMP2 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.